Exact claim · Version 1 · Reviewed 2026-07-23
“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”
A verdict on this wording and scope, not a universal grade for Tirzepatide.
01 · Verdict
Not established
Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.
- Evidence basis
- Randomized human outcomes
- Scope
- The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01Tirzepatide once weekly for the treatment of obesityPubMed · New England Journal of Medicine · Randomized trial · 2022
Defines the evidence limit02Tirzepatide versus semaglutide once weekly in patients with type 2 diabetesPubMed · New England Journal of Medicine · Randomized trial · 2021
Defines the evidence limit
Defines the evidence limit02Tirzepatide versus semaglutide once weekly in patients with type 2 diabetesPubMed · New England Journal of Medicine · Randomized trial · 2021
Defines the evidence limit
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.